A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHC Biopharma Inc.

About this trial

Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced gastrointestinal cancer and determine the recommended dose for subsequent studies.

Eligibility criteria

Qualifiers

1. Fully understand this trial and voluntarily sign the informed consent form. 2. For locally recurrent or metastatic unresectable advanced solid tumors that are diagnosed by histological or cytopathological pathology and cannot be radically treated with radiotherapy, the range-finding stage does not limit specific tumor types and previous treatment conditions.

Disqualifiers

1.Imaging shows that the tumor invades great vessels or is not clearly demarcated from blood vessels.

Trial design

Treatments tested in this trial

  • HC010
  • Paclitaxel
  • Oxaliplatin
  • Capecitabine
  • HC006

Treatment groups

331 Participants
are divided into 3 treatment groups

Sponsors and collaborators